U. S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 8-K
Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934
Date of Report: February 12, 2001
Commission file number 0-19866
-------
CELOX LABORATORIES, INC.
------------------------
(Exact name of small business issuer as
specified in its charter)
MINNESOTA 36-3384240
--------- ----------
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification Number)
1311 HELMO AVENUE, ST. PAUL, MINNESOTA 55128
----------------------------------------- -----
(Address of principal executive offices) (Zip code)
Issuers telephone number, including area code: (651) 730-1500
Item 5. OTHER EVENTS MERGER OF CELOX LABORATORIES, INC WITH PROTIDE
-----------------------------------------------------------
PHARMACEUTICALS, INC.
---------------------
On January 12, 2001. Celox Laboratories, Inc. announced a merger with
its wholly owned subsidiary, Protide Pharmaceuticals, Inc.
Item 7. FINANCIAL STATEMENTS AND EXHIBITS.
----------------------------------
(c.) Exhibits.
*Exhibit 17 Press Release dated January 12, 2001.
- -----------------------------------
SIGNATURE
---------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Celox Laboratories, Inc.
January 29, 2001 By /s/ Milo R. Polovina
Milo R. Polovina, CEO